Markets
Impossible staircase, 1950s.
The first model of the “impossible staircase” (SSPL/Getty Images)

An explosion of speculative call option buying signals the return of retail traders’ favorite weapon

We’re seeing activity that looks an awful lot like gamma squeezes in some of the most speculative stocks.

Luke Kawa
7/21/25 10:12AM

A funny thing happened after the S&P 500 set an all-time high in late June, officially shaking off the tariff-induced tumble.

The benchmark US stock index became pretty boring while an explosion of risk appetite happened below the surface, propelling nonprofitable tech companies, former SPACs fallen from grace, crypto-linked stocks, heavily shorted companies, and other retail favorites sharply higher.

Most of these indexes have reached multiyear, if not record, highs in the process:

Some companies within these baskets have seen their stock prices surge thanks to a clear catalyst, whether that’s Nvidia starting to do business with them or a pivot to holding crypto treasury assets. Some booms, like Opendoor Technologies, have come out of nearly thin air. But what many of them have in common is an underlying market dynamic that’s reinforcing their gains: the gamma squeeze is back

The sequence goes a little something like this: traders buy a ton of call options, and they have to buy them from someone (market makers and/or dealers). These players don’t want to make money by taking the other side of this bet, though. They want to make money through extracting value from every little bit of buying and selling activity that occurs. So when a market maker sells a call — which would leave them exposed to losses if shares of the underlying company rally a ton — they will simultaneously offset that risk by buying a given amount of shares of that company.

When lots of traders are buying options, they are effectively forcing a lot of buying of the underlying stock at the same time! This buying can put upward pressure on the share price, which forces even more buying from these entities that have no view whatsoever on the stock, but are merely trying to cover their butts.

Let’s tie in the Greeks: delta is a term that describes how an option’s price is expected to change based on a $1 shift in the price of the underlying asset. Delta will tend to go up as the stock price goes up. When market makers are buying stock after they’ve sold a call (and buying more if the stock rises after that!), they’re delta-hedging. Gamma is the second derivative of delta; it describes how much the delta is poised to change based on a $1 change in the price action. Gamma is at its highest at the point when the option is at the money. This makes some intuitive sense: whether an option is in the money or out of the money will, at expiration, loosely determine whether or not it has any value.

To sum/to some: the natural response of market makers in an environment where increasing out-of-the-money call option buying propels a stock price higher, pushing that strike in the money and pushing the stock even closer to a higher strike price where another formerly out-of-the-money call option threatens to be money-good, and so on and so forth. It starts to look an awful lot like a perpetual motion money-making machine.

A “gamma squeeze” is the technical explanation for how and why these parabolic moves occur. Market makers are rapidly picking up more deltas, which they need to hedge their exposure because gamma keeps accelerating at different, higher points in the options chain. It’s much easier to see this dynamic play a starring role in smaller stocks and/or ones with constrained float.

This is something that, while very well known by professional options traders, was “discovered” and popularized in the r/WallStreetBets community in early 2020 thanks to… me (whoops). Similar market dynamics played a significant role in the next year’s mania that took shares of GameStop to record highs.

Kawa Post
Source: X, The Trolls of Wall Street

Benjamin Graham, the famous value investor who trained the likes of Warren Buffett, famously quipped, “In the short run, the market is a voting machine but in the long run it is a weighing machine.” 

Well, the gamma squeezes we’re seeing are the market equivalent of stuffing the ballot box in third-world countries.

More Markets

See all Markets
markets

Broadcom’s post-earnings romp continues on heavy volumes

As Broadcom enjoys a rush of new orders from a major new customer (reported to be OpenAI), it’s also reveling in a flood of traffic into the stock.

Volumes are running at 2.5 times their daily average through 1:20 p.m. ET as traders continue to bid up shares in response to the brighter outlook for 2026 revenues, which sent the stock up 9.4% on Friday.

The chip designer is basking in a flood of price target hikes from Wall Street, with Bank of America, JPMorgan, Argus Research, Citigroup, Bernstein, Deutsche Bank, Morgan Stanley, Barclays, Piper Sandler, Rosenblatt Securities, Wells Fargo, and Susquehanna upping their view on how high shares can go since the company reported earnings last week.

Separately, Taiwanese industry outlet DigiTimes is reporting that orders from several other leading tech companies for custom-made Broadcom chips (or ASICs) are “already in the pipeline.” This report has not been corroborated by our own or any other publication’s reporting to date.

markets

SpaceX spectrum deal sends would-be rivals lower

Shares of struggling satellite services company EchoStar soared Monday, after the company — which had recently tottered close to bankruptcy — announced the sale of some of its wireless spectrum licenses to Tesla CEO Elon Musk’s SpaceX for $17 million.

The sale provides a competitive advantage to Musk’s growing Starlink satellite services business, as the licenses it is acquiring from Echostar allows Starlink to operate ground based broadband and cellphone services, the Wall Street Journal reported.

Entities that stood to be hurt by the emergence of a Musk-led SpaceX Starlink service got hit hard on the news. AST SpaceMobile, which has plans to offer a similar satellite-to-consumer cellular service, tumbled.

So did wireless tower providers like Crown Castle and American Tower. Low cost cellular service provider T-Mobile, which had a deal with SpaceX, also slumped, as Luke noted earlier, along with other large wireless telecommunication services providers.

The wireless telecommunications industry grouping within the S&P 500 was down more than 2.5% shortly after noon, making it the worst performing industry within the S&P 500 on Monday.

Entities that stood to be hurt by the emergence of a Musk-led SpaceX Starlink service got hit hard on the news. AST SpaceMobile, which has plans to offer a similar satellite-to-consumer cellular service, tumbled.

So did wireless tower providers like Crown Castle and American Tower. Low cost cellular service provider T-Mobile, which had a deal with SpaceX, also slumped, as Luke noted earlier, along with other large wireless telecommunication services providers.

The wireless telecommunications industry grouping within the S&P 500 was down more than 2.5% shortly after noon, making it the worst performing industry within the S&P 500 on Monday.

markets

Hims rises, Novo dips after FDA releases “green list” of GLP-1 raw material suppliers

Hims & Hers rose and Novo Nordisk slipped in early trading after the US Food and Drug Administration released a "green list" of foreign GLP-1 ingredient suppliers that it considers in compliance with agency standards.

Some telehealth companies like Hims sell copycat versions of Novo's and Eli Lilly’s blockbuster weight-loss drugs through compounding pharmacies, which take the active ingredients from FDA-approved medications and make adjusted, or "personalized,” versions of the drug for patients.

Novo and Lilly have fought against this, arguing that it infringes on their intellectual property. They've sued smaller telehealth providers, pharmacies, and clinics in lieu of any action against them from the FDA. Instead, the FDA gave compounders a list of suppliers it deems safe.

Recent developments in the cases filed by the drugmakers so far as well as the FDA's recent actions suggest telehealth companies may be in a less risky position than investors previously thought. As of Monday morning, prediction markets pegged the likelihood of a suit from Novo against Hims at 34%, down from about 70% earlier this month.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.